clinical trial · NCT06648850
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Applied Biology, Inc.·phase3·not yet recruiting·n = 1,120
Telogen EffluviumFemale Pattern Hair LossFemale Pattern Hair Loss, Androgenic AlopeciaMale Pattern BaldnessAndrogenetic AlopeciaAndrogenetic Alopecia (AGA)DA-001PlaceboPhenylephrineDA-001 Topical + DA-005 Oral (HIF-1α supplement)DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)Phenylephrine Topical 0.25% + Intact Pro TopicalPhenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
brief summary
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
started
May 1, 2026
primary completion
Mar 19, 2027
completion
Apr 26, 2027
last updated
Apr 13, 2026
detailed description
DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist. DA-001 was studied in a population of women that suffer from excessive hair shedding. DA-001 demonstrated significant reduction in hair shedding.
This study aims to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol